Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

n Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITT	AL
FORM	

(to be used for all correspondence after initial filing)

Application Number	10/572,696
Filing Date	October 5, 2006
First Named Inventor	Edith Gardiner
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	42-000400US

		Examiner Name		Unassigned
Total Number of Pages in This Submission	on	Attorney Docket Numbe	r	42-000400US
	ENCLOS	SURES (check all that ap	ply)	
Fee Transmittal Form	PTO-1	449 Form		After Allowance Communication to Group
Fee Attached	Cited F	References		Appeal Communication to Board of Appeals and Interferences
Amendment / Response	Сорус	of PCT Search Report		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
Amendment and Request for Reconsideration	Сорус	of EP Search Report		Proprietary Information
Affidavits/declaration(s)	1	to Convert to a nal Application		Status Letter
Extension of Time Request	Power o	of Attorney, Revocation of Correspondence		Additional Enclosure(s) (please identify below):
X Receipt Acknowledgement Postcard	=-	l Disclaimer ntity Statement		
X Information Disclosure Statement		t for Refund		
Response to Missing Parts/ Incomplete Application	ise charge D paper or dur	c Charge Deposit Account eposit Account No. 50-0893 ing the pendency of this appl of the documents enclosed.	for any ication	additional fees associated with including any extensions of time
Parts under 37 CFR 1.52 or 1.53		J		,
SIGNATURE	OF APPLI	CANT, ATTORNEY, OR	AGE	VT
Firm or Individual name Jonathan Alan Quir	ne, Reg. N	o. 41,261, Quine Intelle	ctual	Property Law Group, P.C.
Signature Auth Al	le Qui			
Date January 8, 2007				
C	ERTIFICA	ATE OF MAILING		
I hereby certify that this correspondence is being f sufficient postage as first class mail in an envelope	acsimile trans	mitted to the USPTO or deposit		

11	~~1.	1-				
-						
Ιy	pea	or	prin	itea	nar	ne

Signature

Date

1/8/07



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on January 8, 2007

By Chiant April

Attorney Docket No. 42-000400US Client Ref. No. 127444

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Edith Gardiner, et al.

Application No.: 10/572,696

Filed: October 5, 2006

International Filing Date: September 18, 2003

For: METHODS OF MODULATING

BONE GROWTH, BONE

REMODELING AND ADIPOSITY

Confirmation No. 5276

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97 and

§ 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. *Copies of the cited US Patent applications and US Publications have not been enclosed because they are no longer required by the office for submission.* It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Edith Gardiner, et al.

Application No.: 10/572,696

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Jonathan Alan Quine, J.D., Ph.D.

Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

P.O. BOX 458

Alameda, CA 94501

(510) 337-7871

Fax (510) 337-7877

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

Substitute for form 1449 8/PTO	Complete if Known			
Substitute for form 14494-57-10	Application Number 10/572,696			
INFORM APPLICATION OF THE PROPERTY OF THE PROP	Filing Date	October 5, 2006		
		International Filing Date: September 18, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Edith Gardiner		
	Group Art Unit	1646		
	Examiner Name	Unassigned		
(use as many sheets as necessary)	Attorney Docket Number	42-000400US		
	Date Submitted	January 8, 2007		

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Docur Number	nent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
	1	5,968,819		Gerald et al.	10/19/1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Office	Foreign Patent Docum Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	2	wo	00/00606 A1		Garvan Inst of Med Rsch.	01/06/2000		
	3	wo	01/53477 A1		Baylor Coll of Med.	07/26/2001		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т				
	4	BALDOCK ET AL. (2002) Hypolathalmic Y2 receptors regulate bone formation . J. Clin Invest. 109(7) 915-921.					
	5	BLOCK ET AL. (2002) Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesity. J. Med Chem.45:3509-3523.					
	6	CABRELE ET AL. (2000) Molecular characterisation of the ligand-receptor interaction of the neutropeptide Y family. J. Peptide Sci 6:97-122.					
	7	CHAMORRO ET AL. (2002) Appetite suppression based on selective inhibition of NPY receptors. Int. J. Obes. 26:281-298					
	8	DUHAULT ET AL. (2000) Food intake in rodents: Y5 or Y1 NPY receptors or both? Can J. Physiol Pharm. 78:173-185.					
	9	HANSEL ET AL. (2001) Neuropeptide Y functions as a neuroproliferative factor. Nature 410 (6831) 940-944.					
	10	HERZOG (2002) Hypothalmic Y2 receptors: central coordination of energy homeostasis and bone mass regulation. Drug News Perspect 15(8): 506-510.					
	11	IYENGAR ET AL. (1999) Characterzation of neuropeptide Y induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding? J. Pharm Exp Ther. Whole document.					
	12	KUSHI ET AL. (1998) Obesity and mild hyperinsulinaemia found in neuropeptide Y-Y1 receptor deficientmice. Proc Nat Acad Sci USA 95:15659-64					
	13	PARKER ET AL. (2002) Neuropeptide Y receptors as targets for anti-obesity drug					
Examine Signature		Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no person		information unless it contains a valid OND control number.
Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number_	10/572,696
INFORMATION DISCLOSURE	Filing Date	October 5, 2006
·		International Filing Date: September
		18, 2003
STATEMENT BY APPLICANT	First Named Inventor	Edith Gardiner
	Group Art Unit	1646
	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	42-000400US
	Date Submitted	January 8, 2007

		development: perspective and current status. Eur J. Pharm 440:173-187
	14	SAINSBURY ET AL. (2002) Important rile of hypothalmic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Nat Acad Sci USA 99(3):8938-8943.
	15	SAINSBURY ET AL. (2003) Synergistic effects of Y2 and Y4 receptors on adiposity and bone mass revealed in double knockout mice. Mol Cell Biol 15:5225-5233.
,	16	TANG-CHRISTENSEN ET AL. (1998) Central administration of Y5 antisense decreases spontaneous food intake and attenuates feeding in response to exogenous neuropeptide Y. J. Endo 159:307-312.
	17	Copy of International Search Report for PCT/AU03/01227
	18	Copy of Written Opinion for PCT/AU03/01227
	19	Copy of International Preliminary Examination Report for PCT/AU03/01227

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.